Natco Pharma Q2 FY26 – ₹518 Cr Profit, ₹1,363 Cr Sales & 7 FDA Love Letters Later: The API Avengers Return
1. At a Glance
Natco Pharma is that one Hyderabad overachiever who juggles R&D, FDA inspections, and court battles like a Tollywood hero dodging bullets in slow-motion. The stock closed at ₹865 (down – 0.52%) with a market cap of ₹15,489 Cr, P/E 10.1, and ROE 28% – numbers any pharma analyst would swipe right on.
Yet, behind the scientific glamour sits a quarterly reality check: Sales ₹1,363 Cr, PAT ₹518 Cr, down 23.5 % QoQ, because apparently, even blockbuster generics have intermissions. Operating margins still command a royal ~42 %, proving Natco’s cost discipline is tighter than an FDA Form 483 checklist.
The company’s export formulations now make up 44 % of the pie (vs 73 % FY23), domestic formulations 15 %, and contract manufacturing 29 % – clearly, Natco is spreading its chemistry like ghee on a paratha.
And just as analysts were sipping coffee, the US FDA gifted seven Form-483 observations (Nov 2025, Manali API unit). Because in pharma, “love letters” from regulators are part of the romance.
2. Introduction
Once upon a time, Natco was a modest API shop. Today, it’s an international pharma drama: court battles, patent settlements, and now a US $226 Mn South African fling (Adcock Ingram acquisition). Think of it as the RRR of Indian pharma – R&D, Regulations, and Revenue diversification.
From oncology to agrochemicals, Natco sells everything from anti-cancer tablets to pest repellents – essentially fighting diseases in both humans and tomatoes. The domestic oncology brand is so entrenched that oncologists prescribe it faster than the stock price corrects post-results.
While the market keeps asking, “Why the drop from ₹1,500 to ₹865?”, management answers with new filings, niche launches, and dividend cheques. FY25 delivered record ₹4,784 Cr revenue and ₹1,883 Cr profit, only for FY26 guidance to promise – 30 % profit. A little melodrama keeps investors awake.
Yet, when your ROCE 33 % and debt : equity 0.03, you can afford a few Bollywood plot twists.
3. Business Model – WTF Do They Even Do?
Natco is the three-in-one shampoo of pharma – Formulations + APIs + Contract Manufacturing, now with a dash of Agro Science.
Export Formulations (44 %): their bread, butter, and occasionally champagne. Partnering with giants like Teva, Mylan, Lupin, they play the “first-to-file Para IV” game – the legal version of musical chairs.
Domestic Formulations (15 %): oncology and specialty pharma. A 850-person sales army ensures doctors remember “Natco” even in their dreams.
Crop Sciences (2 %): an ambitious bet on pesticides; target ₹130-140 Cr revenue FY26.
Contract Manufacturing (29 %): 40 + products for major Indian names – Natco’s profitable freelancing gig.
Eight plants, two R&D centres, and 570 patents later, Natco looks less like a pharma company and more like a scientific version of Dmart – quietly efficient, occasionally scandalous.
